Linked Data API

Show Search Form

Search Results

1716806
registered interest false more like this
date less than 2024-05-09more like thismore than 2024-05-09
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care remove filter
answering dept sort name Health and Social Care more like this
hansard heading Enzyme Replacement Therapy more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if she will make an assessment of the adequacy of the availability of enzyme replacement therapy. more like this
tabling member constituency Jarrow more like this
tabling member printed
Kate Osborne more like this
uin 25591 remove filter
answer
answer
is ministerial correction false more like this
date of answer less than 2024-05-15more like thismore than 2024-05-15
answer text <p>We are aware of the supply issues with the three enzyme replacement therapies, Creon 10,000 gastro-resistant capsules, Creon 25,000 gastro-resistant capsules, and Nutrizym 22 capsules. These are due to manufacturing and active pharmaceutical ingredient constraints. The Department will be issuing updated guidance to healthcare professionals regarding treatment of patients while there is a disruption to the supply of these pancreatic enzyme replacement therapies. We are having regular conversations with the suppliers of these products to help drive the resolution of these issues as quickly as possible, for example by expediting orders and increasing forecasts. We are also working with specialist importers to source unlicensed imports from abroad.</p><p>Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.</p>
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
grouped question UIN
25370 more like this
25371 more like this
question first answered
less than 2024-05-15T08:18:01.063Zmore like thismore than 2024-05-15T08:18:01.063Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4783
label Biography information for Kate Osborne more like this